The results from Soliton Inc‘s pivotal cellulite trial will be now be presented at the AAD 2020 Annual Meeting, to now be held virtually in the next 6-8 weeks, the company announces in a media release.
The company received notice on Friday, March 20, 2020, that The American Academy of Dermatology (AAD), which was recently forced to cancel its annual dermatology conference due to the coronavirus (COVID-19), is making plans to conduct its conference through a digital event highlighting content that would have been presented at the annual meeting.
Soliton’s previously accepted oral presentation regarding its pivotal cellulite clinical trial results is expected be presented in a pre-recorded webcast by Dr. Elizabeth Tanzi, the lead investigator on the trial and member of Soliton’s Scientific Advisory Board. Details for the virtual presentation will be announced in the coming weeks.
“We are excited and appreciative that the American Academy of Dermatology has planned to host their Annual Meeting virtually this year. We are thankful for the opportunity to share with the physician and dermatology community Soliton’s pivotal results regarding the potential of the RAP device to improve the appearance of cellulite,” Christopher Capelli, MD, founder, President and CEO of Soliton, says in the release.
[Source(s): Soliton Inc, PR Newswire]
